To begin with, we will explore the foundational principles of genes and protein products in the context of in vivo gene editing. This segment will discuss current technologies, applications, and future directions in the field of in vivo gene editing.

Following this, we will delve into ex vivo gene editing, including CAR-T cell therapy. We will address applications in this domain, providing an overview of the current state of ex vivo gene editing technology.

Lastly, we will address the ethical and regulatory considerations associated with both in vivo and ex vivo gene editing. This will include specific considerations for Institutional Review Boards (IRB), such as consent forms, long-term follow-up, data monitoring, and discuss the importance of having prospective plans in place for scenarios where protocols do not proceed as expected.